# OnCo record paper-nrg-gy018-nejm-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-nrg-gy018-nejm-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-nrg-gy018-nejm-2023" ;
  schema:name "NRG-GY018: pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer"@en ;
  schema:description "Adding pembrolizumab to carboplatin-paclitaxel and continuing it as maintenance cut the risk of progression by 70 percent in mismatch repair-deficient endometrial cancer and by 46 percent in mismatch repair-proficient disease."@en ;
  schema:url <https://onco.cc/key-papers/paper-nrg-gy018-nejm-2023/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2302312>, <https://pubmed.ncbi.nlm.nih.gov/36972022/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2302312> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Eskander RN, Sill MW, Beffa L, et al." ;
  onco:cancers <https://onco.cc/cancers/advanced-recurrent-endometrial-cancer/>, <https://onco.cc/cancers/endometrial-mmr-deficient/>, <https://onco.cc/cancers/endometrial-nsmp/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:journals <https://onco.cc/journals/nejm/> .